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OBJECTIVE — Subjects with the diagnosis of latent autoimmune diabetes in adults (LADA)
are more prone to need insulin treatment than those with type 2 diabetes. However, not all
patients with LADA develop the need for insulin treatment, indicating the heterogeneity of
LADA. We investigated this heterogeneity by comparing phenotypes of LADA with and without
perceived need for insulin treatment (data obtained at times when diagnosis of LADA was not
investigated) and also compared LADA and type 2 diabetes phenotypes.
RESEARCHDESIGNANDMETHODS — Weuseddatafromtheallpopulation–based
Nord-TrøndelagHealthstudy(n64,931),performedin1995–1997.Datawereassembledfor
individuals with LADA (n  106) and type 2 diabetes (n  943).
RESULTS — InthecomparisonofindividualswithLADAbothwithandwithouttheneedfor
insulin, insulin-treated subjects had higher titers of GAD antibodies (P  0.001) and lower
fasting C-peptide levels (P  0.001). GAD antibodies and C-peptide correlated negatively (r 
0.40;P0.009).InthecomparisonofindividualswithLADAandtype2diabetes,allwithout
the need for insulin, markers of metabolic syndrome were equally prevalent and pronounced.
Age, C-peptide, and glucose levels were also similar. In the comparison of insulin-treated indi-
viduals with LADA and type 2 diabetes, more patients with LADA received insulin (40 vs. 22%,
P  0.001) and C-peptide levels were lower (P  0.001). Patients with LADA were leaner but
were still overweight (mean BMI 28.7 vs. 30.9 kg/m
2 in type 2 diabetes, P  0.001). In the
comparison of type 2 diabetic patients with and without insulin, insulin-treated subjects were
more obese and had higher A1C and lower C-peptide levels (P  0.001).
CONCLUSIONS — Our conclusions are that 1) the need for insulin treatment in LADA is
linked to the degree of autoimmunity and -cell failure, 2) subjects with LADA and type 2
diabetes without the need for insulin treatment are phenotypically similar, and 3) insulin treat-
mentintype2diabeticpatientsisassociatedwithbothinsulinresistanceand-cellinsufﬁciency.
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A
utoimmunity is the major cause of
type 1 diabetes. Autoimmunity is
also assumed to be the major cause
of latent autoimmune diabetes in adults
(LADA) because this category of diabetes
shares biochemical markers of -cell–
directedautoimmunitywith“classic”type
1 diabetes. In clinical practice, autoim-
munityinclassictype1diabetesaswellas
in LADA is usually documented by anti-
bodies against GAD.
LADA is considered a “mild” form of
type 1 diabetes. Mild indicates the fact
thatpatientswithLADAdonotbyclinical
judgment need insulin from the time of
diagnosis. However, within the ﬁrst few
yearsafterthediagnosisofdiabetesaneed
for insulin treatment develops in many
patients with LADA. This distinguishes
patients with LADA from those with non-
autoimmune type 2 diabetes in whom a
need for insulin treatment develops later
than in those with LADA (1). An early
needforinsulintreatmentinpatientswith
LADA points to ongoing autoimmune-
mediated destruction of -cells in these
patients.
Risk factors for type 2 diabetes, such
as age, obesity, and lack of physical activ-
ity, are associated with the development
of LADA (2). In fact, odds ratios in terms
of risk for diabetes for these factors of in-
sulin resistance were the same for LADA
and type 2 diabetes. This raises the ques-
tion of the relative importance of autoim-
munity vis-a `-vis insulin resistance for the
etiology of LADA and whether etiology
differs among patients with LADA. Sup-
port for etiological heterogeneity comes
from the large UK Prospective Diabetes
Study (UKPDS), in which only a minority
of patients with the diagnosis of LADA,
when deﬁned solely as GAD antibody pos-
itivity, developed the need for insulin treat-
ment during 6 years of follow-up (1). The
heterogeneityofLADAisalsoevidentwhen
one compares phenotypes of patients with
LADA in different studies (3–6).
Heterogeneity of patients with LADA
could be further elucidated by comparing
phenotypes of insulin-treated patients
with LADA with those not treated with
insulin.However,severalconditionshave
to be met for such comparisons to be
valid. First, groups of diabetic subjects to
be compared must be drawn from the
same geographically deﬁned population.
A population-based study is necessary to
avoid the possible biases incurred by
studying referral patients or patients se-
lected for inclusion in clinical interven-
tionstudies.Second,theperceivedneedfor
insulin treatment has to be unbiased by
LADA classiﬁcation, because it has been
shown that insulin treatment is initiated
earlierwhenpriorknowledgeofautoimmu-
nity, measured as GAD antibodies, is avail-
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insulin-treated and non–insulin-treated
type 2 diabetic patients from the same pop-
ulation must be at hand.
We had the opportunity to study pa-
tients with LADA and type 2 diabetes ful-
ﬁlling the above-mentioned conditions,
who were identiﬁed and characterized in
the Nord-Trøndelag (HUNT) study. The
HUNT study was performed between
1995and1997.Thestudywasopentoall
adult subjects (90,000) living in a geo-
graphically deﬁned area and had a high
attendance rate (70%). To our knowl-
edge, the patients with LADA and type 2
diabetes deﬁned in the HUNT study did
not participate in any study at the time of
diagnosis and initiation of treatment,
thereby minimizing any deviation from
standard clinical practice and obviating
increased attentiveness for signs of insuf-
ﬁcient metabolic control and insulin re-
quirement. Further, autoantibodies, such
asGADantibodies,werenotmeasuredby
doctors (general practitioners) responsi-
ble for treatment in the region as part of
the diabetes workup before and at the
time of assembling data in 1995–1997.
Thus, patients with autoimmune diabetes
not requiring insulin at time of diagnosis
were regarded and treated as type 2 dia-
betic patients. This assumption provided
a unique opportunity to use the need for
insulin as clinically perceived as a param-
eterforsubclassifyingpatientswithLADA
and to compare phenotypes of insulin-
treated and non–insulin-treated patients
withLADAwithrespectivegroupsoftype
2 diabetic patients. Speciﬁcally, we
wished to assess the inﬂuence of autoim-
munity and -cell insufﬁciency vis-a `-vis
insulinresistancefactorsfortheperceived
needforinsulintreatmentinpatientswith
LADA.
RESEARCH DESIGN AND
METHODS— The second Nord-
Trøndelag Health (HUNT 2) study was
conducted between 1995 and 1997. All
inhabitants aged 20 years or older (n 
92,703)inNord-TrøndelagCounty,Nor-
way, were invited to participate in the
study, and 65,282 (70.4%) accepted the
invitation and attended a clinical exami-
nation. The participants were asked to ﬁll
outself-administeredquestionnaireswith
health-andlifestyle-relateditems,suchas
general health, smoking, marital status,
and education. The clinical examination
includedmeasurementsofbloodpressure
(Dinamap 845XT; Critikon), heart rate,
height, weight, and waist circumference.
Measurements were performed by a spe-
cially trained nurse or technician.
A nonfasting blood sample was taken
from all participants for analyses in sera.
Remaining sera were stored at –70°C.
Blood sampling and questionnaire in
diabetic patients
The 1,952 participants who reported dia-
betes in the initial questionnaire were
asked to ﬁll out an additional question-
naire with speciﬁc questions on diabetes
such as duration of known disease and
antidiabetes and other medication. For
insulin treatment, the questionnaire
asked for starting date and the current
dosage of insulin. The questionnaire con-
tained three questions regarding cardio-
vascular disease: “Have you ever suffered
from angina pectoris?”, “Have you ever
suffered from myocardial infarction?”,
and “Have you ever suffered from
stroke?”, with the alternatives of answer-
ing being “yes” or “no.” A history of car-
diovascular disease was deﬁned as
positive when at least one of the three
questions was answered with “yes.”
In addition, subjects were asked to
submit a blood sample after an overnight
fast. Blood was drawn for analyses of glu-
cose, C-peptide, and GAD antibodies. Of
the 1,511 diabetic subjects who partici-
pated in both the questionnaire and the
supplemental blood sampling part of the
study, 128 were classiﬁed as having
LADA 1,133 as having type 2 diabetes,
and 123 as having type 1 diabetes. In ad-
dition, 64 subjects were classiﬁed as hav-
ing gestational diabetes mellitus or
mature-onsetdiabetesoftheyoungornot
havingdiabetes.Anequalnumberofsub-
jects could not be classiﬁed because they
did not ﬁt into any of the predeﬁned cate-
goriesofdiabetes.Further,oftheclassiﬁable
subjects,22(17%)ofthoseclassiﬁedashav-
ing LADA and 190 (16.8%) of those classi-
ﬁed as having type 2 diabetes were
excluded from our study because of the
lackofthenecessaryinformationoninsu-
lin treatment.
Assays
A1C was analyzed with the Architect
ci8200/c8000 system and fasting glucose
with a HemoCue monitor at Levanger
Hospital,Levanger,Norway.Serumlevels
of C-peptide in the overnight-fasted state
and GAD antibodies were analyzed at
Aker Hospital, Oslo, Norway. C-peptide
was measured with a radioimmunoassay
method (Diagnostic System Laboratories,
Webster, TX). GAD antibodies were mea-
sured by immunoprecipitation, using
[
3H]leucinetranslation-labeledGAD65as
an indicator. The level of GAD antibodies
wasexpressedasanindexvaluerelativeto
a standard serum. An index 0.08 was
considered as positive. The method in-
cluding the antibody used was adapted
from Peterson et al. (8). Proﬁciency was
tested at Aker Hospital in a diabetes auto-
antibody standardization program. The
specimen for analysis was then blinded,
with 100 samples from control subjects
and 50 samples from type 1 diabetic sub-
jects being analyzed. At the cutoff level of
0.08, the sensitivity was 0.64 and the
speciﬁcitywas1.00.CholesterolandHDL
cholesterolweremeasuredinthenonfast-
ing state by routine methods.
Classiﬁcation of diabetes
Diabetes was classiﬁed as follows:
LADA:GADantibodytiter0.08and
lifestyle and oral therapy or insulin treat-
ment started later than 12 months after
diagnosisorinsulintherapystartedbefore
12 months after diagnosis, but with fast-
ing C-peptide 150 pmol/l. (Six subjects
were classiﬁed as having LADA according
to the latter criterion; their C-peptide lev-
els ranged between 158 and 2,366 pmol/l.)
Type 2 diabetes: Lifestyle and oral
therapy or insulin treatment started later
than 12 months after diagnosis and GAD
antibody titer 0.08.
Type 1 diabetes (excluded from this
study): Insulin treatment started before
12 months after diagnosis, either with a
GAD antibody titer 0.08 or GAD anti-
body titer 0.08 and C-peptide 150
pmol/l.
Statistical analyses
We reported chronological age, age at di-
agnosis of diabetes, diabetes duration,
GAD antibodies, insulin dosage, and
years before the start of insulin as an un-
adjusted mean  SEM. We compared
mean values with 95% CIs, adjusted for
age,sex,anddiabetesdurationfordataon
blood pressure, BMI, waist circumfer-
ence, total cholesterol–to–HDL choles-
terol ratio, fasting glucose, A1C, and
fasting C-peptide, using a general linear
model. Levels of C-peptide were not nor-
mally distributed and therefore were log
transformed before calculation of the
adjusted mean value. Results were con-
sidered signiﬁcant when P  0.05. Cor-
relation tests were performed using
Spearman’s rank correlation. All analy-
ses were performed using the statistical
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Chicago, IL).
Consent
Participation was voluntary, and each
participantprovidedwrittenconsent.The
studies were approved by the regional
ethics committee and by the Norwegian
Data Inspectorate.
RESULTS
Comparison of insulin-treated and
non–insulin-treated subjects with
LADA
Ageandsexdistributionwerecomparable
between the insulin- and the non–
insulin-treated subjects with LADA. Dia-
betes duration was longer in those
receiving insulin (Table 1). Fasting blood
glucoseandA1Cweresigniﬁcantlyhigher
and fasting C-peptide was signiﬁcantly
lower in the insulin-treated subjects. The
GAD antibody titer was signiﬁcantly
higher in the insulin-treated subjects.
Therewasatendencyforacorrelationbe-
tween the GAD antibody titer and diabe-
tes duration before the start of insulin
treatment (P  0.07). There was a nega-
tive correlation between the GAD anti-
body titer and C-peptide in the insulin-
treated LADA group (correlation
coefﬁcient, r  0.40; P  0.009). Such
a correlation was not readily apparent
within the LADA group without insulin
treatment (r  0.22; P  0.09). The
degree of overweight measured as BMI
andwaistcircumferencedidnotdifferbe-
tween groups nor did blood pressure.
Comparison of non–insulin-treated
subjects with LADA with
non–insulin-treated subjects
with type 2 diabetes
Age,sex,anddiseasedurationdidnotdif-
fer between these two groups (Table 1).
There was no difference in blood pres-
sure, lipid status, or adiposity (Table 2).
The proportion of sulfonylurea-treated
patients was identical. The use of other
oral antidiabetic medications also was
evenlydistributedinthetwogroups(sup-
plemental Table 1, available in an online
appendix at http://dx.doi.org/10.2337/
dc08-1468).
Further, there were no differences in
fasting C-peptide or fasting glucose be-
tween groups. Also, the frequency of his-
tory of cardiovascular disease did not
differ signiﬁcantly (present in 25% of pa-
tientswithLADAvs.29%ofpatientswith
type 2 diabetes). Results were similar
when we excluded subjects receiving sul-
fonylurea treatment (Table 2).
Comparison between insulin-treated
patients with LADA and insulin-
treated patients with type 2 diabetes
Age and sex were comparable in insulin-
treated patients with LADA and insulin-
treated patients with type 2 diabetes.
There was no signiﬁcant difference in di-
abetes duration. A larger percentage of
patients with LADA were treated with in-
sulin(40%ofthosewithLADAvs.22%of
those with type 2 diabetes; P  0.001)
(Table1).Themeandurationbetweendi-
abetes diagnosis and start of insulin treat-
ment was not signiﬁcantly shorter in the
patients with LADA (P  0.157), and the
mean daily dosage of insulin was not sig-
niﬁcantly different either (P  0.195 for
lower dosage in patients with LADA).
Insulin-treated patients with type 2
diabeteshadhigherBMI,waistcircumfer-
ence,andcholesterol-to–HDLcholesterol
ratios than the insulin-treated LADA
group.FastingC-peptidewashigherthan
that in the insulin-treated LADA group.
The frequency of microalbuminuria was
not signiﬁcantly different (37% of pa-
tients with type 2 diabetes vs. 27% of pa-
tients with LADA; P  0.072), whereas a
history of cardiovascular disease was
more frequent in the insulin-treated type
2 diabetes group (37 vs. 29%; P  0.031)
despite a comparable degree of smoking.
Comparison between insulin-treated
and non–insulin-treated patients
with type 2 diabetes
Type2diabeticpatientswhoweretreated
with insulin were more obese and had
higher A1C and lower C-peptide levels
than subjects who were not treated with
insulin(Table2).Theinsulin-treatedsub-
jects had a more frequent history of car-
diovascular disease (36 vs. 28%; P 
0.031).
CONCLUSIONS — Our study shows
strong evidence for an overriding role of
autoimmunity, assessed from GAD anti-
bodies, behind a perceived need for insu-
lin treatment in patients with LADA. In
contrast,weﬁndnophenotypicinﬂuence
of autoimmunity in those patients with
LADA who were not treated with insulin.
A major role for autoimmunity be-
hind a need for insulin is indicated by
insulin-treated patients with LADA hav-
ing higher GAD antibody titers than pa-
tients not treated with insulin. Further,
we ﬁnd a strong negative correlation be-
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hand and levels of C-peptide on the other
in the insulin-treated LADA group. A ma-
jor role for autoimmunity is also sup-
ported by the lack of evidence for insulin
resistance factors being operative. Thus,
neitheradipositynorotherparametersas-
sociated with metabolic syndrome, such
as hypertension or dyslipidemia, were
more pronounced in insulin-treated ver-
sus non–insulin-treated patients with
LADA. This result was in contrast with
ﬁndings in the corresponding groups of
type 2 diabetic patients in whom obe-
sity was more marked in those with a
perceived need for insulin treatment.
However, patients with LADA receiving
insulin were overweight. Therefore, it
remains possible that insulin resistance
(obesity being a marker thereof) acts as
a permissive factor for the need for in-
sulin treatment in these patients.
Our results are in line with those of
Genovese et al. (4), who found that pa-
tientswithahighGADantibodytiterwere
more frequently receiving insulin ther-
apy. Also, Buzzetti et al. (9) found that
patients with high titers had more prom-
inent traits of insulin deﬁciency and a
proﬁle of more severe autoimmunity. In-
terestingly, the latter study reported a bi-
modaldistributionofGADantibodytiters
that identiﬁed distinct subgroups of pa-
tients. We did not ﬁnd a bimodal distri-
bution(resultsnotshown).Differencesin
study populations could possibly explain
this discrepancy: Buzzetti et al. recruited
their patients from diabetes centers,
whereas our patients were recruited from
an all population–inclusive survey.
We found no signiﬁcant difference in
phenotypes between non–insulin-treated
patients with LADA and non–insulin-
treated patients with type 2 diabetes. We
did not verify GAD antibody positivity by
repeat measurements; however, the high
speciﬁcity of our GAD antibody assay
strongly indicates that the presence of
GAD antibodies is indeed a marker of au-
toimmunity. The question arises whether
GAD antibody positivity in non–insulin-
treated patients with LADA was of any
clinical signiﬁcance at the time of collec-
tion or later. The observation that up to
4% of a nondiabetic population harbors
GAD antibodies (10–12) suggests that
autoimmunity as measured by GAD anti-
bodies toward insulin-producing -cells
canexistwithoutclinicallymeasurableef-
fects. If so, the genetics of diabetes in our
non–insulin-treated patients with LADA
should be similar or identical to that of
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agrees with our previous ﬁnding that a
family history of diabetes was as strong a
risk factor for LADA as for type 2 diabetes
but was a lesser risk factor for type 1 dia-
betes(13).Furthermore,genesassociated
with type 2 diabetes have recently been
found to be associated also with LADA
(14).Ageneticbackgroundsimilartothat
for type 2 diabetes could possibly be the
most inﬂuential factor in patients with
LADA who were not treated with insulin.
If so, this could explain a seemingly par-
adoxical ﬁnding of ours (13) and others’
(15), namely that GAD antibody titers are
negativelyassociatedwithafamilyhistory
of diabetes in patients with LADA.
A comparison of insulin-treated pa-
tientswithLADAandinsulin-treatedtype
2 diabetic patients revealed lower fasting
C-peptide levels in insulin-treated pa-
tients with LADA. Also BMI and waist
circumferencewerelowerintheinsulin-
treated LADA group than in the corre-
sponding type 2 diabetic group. These
ﬁndings suggest that the decision to start
insulin treatment in type 2 diabetic pa-
tients was, in contrast to the situation in
patientswithLADA,basedtosomeextent
on insulin resistance–induced poor met-
abolic control. This notion is supported
by more marked adiposity in insulin-
treatedthaninnon–insulin-treatedtype2
diabetic patients. One should, however,
also recognize a strong element of insuli-
nopenia in the insulin-treated type 2 dia-
betic patients. Thus, C-peptide levels
were signiﬁcantly lower in these patients
thaninthosewithtype2diabeteswithout
insulin treatment, even after taking into
account the increase in insulin secretion
due to sulfonylurea treatment in the latter
group. These ﬁndings are in line with the
successive -cell deterioration known to
occur with increasing duration of type 2
diabetes (16,17).
Previous studies, including the large
UKPDS (1), demonstrated a markedly
shorter time interval from diagnosis to in-
sulin treatment in patients with LADA
than in type 2 diabetic patients. In our
study population we found only a ten-
dency for a shortening of duration before
insulin. Two explanations may be offered
for the partial discrepancy with earlier
studies. First, the fact that our patients
were not part of any study may have de-
layed the decision to start insulin treat-
ment. Second, and most important, our
classiﬁcation of LADA required a longer
time without insulin treatment, i.e., a
whole year after diagnosis, than that in
other studies, such as the UKPDS. The
rationale for our classiﬁcation was to ob-
tainaclearseparationbetweenLADAand
classic type 1 diabetes. Were we to in-
cludepatientswiththeperceivedneedfor
insulin already between 6 and 12 months
after diagnosis of diabetes (16 individuals
in all), then the difference in time to insu-
lin treatment was signiﬁcant between
LADA and type 2 diabetes (results not
shown).
Our study has strengths and limita-
tions. A strength and prerequisite for the
validity of the present comparisons is that
we have studied diabetic subjects who
were recognized and categorized as part
of a large geographically deﬁned and all
population–inclusive survey. To the best
of our knowledge, our study is unique in
this respect. Also, the participation rate
was comparatively high and probably
representative of all diabetes in Nord-
Trøndelag. In this context, it is of interest
that measurements of GAD antibodies in
330 of the unclassiﬁed diabetic subjects
detected 17 subjects with diabetes onset
35yearsofagewhowereGADantibody
positive (E. Petterson, K. M., V. G., un-
published observations). Had we in-
cluded this small number of patients with
probable LADA, the conclusions of our
study would not have changed. On the
other hand, the cross-sectional design of
our study is an obvious limitation and
should be kept in mind when the present
results are interpreted.
In summary, our study suggests that
autoimmunity plays a major role in the
perceivedneedforinsulininpatientswith
LADA despite the fact that a certain de-
gree of overweight and insulin resistance
is present. Further, we did not ﬁnd phe-
notypic differences between those pa-
tientswithLADAandtype2diabeteswho
werenotreceivinginsulin.Theseﬁndings
highlight heterogeneity in patients with
LADA as currently deﬁned.
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